BMY

Recent Articles

5 Stocks to Buy in No-Good, Stinkin’ May

May isn't the cruelest month, but historically it's been tough for investors to find quality stocks to buy. Happily, these names fit the bill. More 

These 54 Big Blue Chips Are On the Move

During these busy times it pays to stay on top of the latest blue chip opportunities. Today's blog post is a great place to start with these updated ratings More 

Trade of the Day: Nautilus, Inc. (NYSE:NLS)

Nautilus (NLS) shares fell 3.7% Monday on no news, offering traders a phenomenal entry point. More 

Start the Week Right With These 61 Trades

During these times it pays to stay on top of the latest profit opportunities. Today's post is a great place to start with these changes to our stock ratings More 

4 Healthcare Stocks on Shaky Ground – MRK LLY AZN BMY

Biotechnology stocks have broken down, and certain pharmaceutical stocks are now following suit. Could Merck and other pharmas suffer more downside? More 

The 5 Best Mutual Funds to Buy for 2016

Nailing down the best mutual funds for 2016 was no easy task but we found five that could be top performers. More 

GSK, BMY: GlaxoSmithKline to Buy Bristol-Myers HIV Drug

GlaxoSmithKline (NYSE:GSK) is buying HIV drugs produced by Bristol-Myers (NYSE:BMY). The Bristol-Myers medication will cost GlaxoSmithKline up to $1.5 billion, making it an even stronger U.K. pharmaceutical giant. The company will shell out $317 million upfront for the drugs, which treat late-stage HIV. An additional $518 million will be paid depending on particular development and... More